-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Under normal circumstances, the body will maintain blood glucose levels in the range of about 70-110 milligrams per deciliter (mg/dL) or 3.
Hypoglycemic diabetes
Zealand Pharma injection therapy Zegalogue has received US Food and Drug Administration Administration ( the FDA approved) can be used for the treatment of severe hypoglycemia in diabetic patients.
Manage FDA
The efficacy data of three phase III clinical studies conducted by Zegalogue (dasiglucagon) in children aged 6 to 17 years and adults with type 1 diabetes support the FDA approval.
Type 1 diabetes in children For all three studies, the primary efficacy endpoint is the time to plasma glucose recovery, defined as an increase in blood glucose of ≥20 mg/dL from the date of administration, and no additional intervention within 45 minutes.
Compared with placebo, the median time of blood glucose recovery in patients at 10 minutes after Zegalogue administration was "significantly" faster, while the data in the placebo group was 30-45 minutes.
Original source:
Original source:href="" target="_blank" rel="noopener">
